Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1975 1
1981 1
1983 1
1984 1
1985 1
1986 4
1988 4
1989 1
1990 3
1991 1
1993 2
1994 2
1995 1
1996 3
1997 3
1998 1
1999 4
2000 3
2002 7
2003 4
2004 7
2005 5
2006 5
2007 15
2008 20
2009 41
2010 39
2011 59
2012 58
2013 58
2014 60
2015 63
2016 42
2017 32
2018 20
2019 22
2020 14
2021 5
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 20199137

543 results
Results by year
Filters applied: . Clear all
Page 1
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S; LEAD-1 SU study group. Marre M, et al. Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x. Diabet Med. 2009. PMID: 19317822 Free PMC article. Clinical Trial.
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes.
Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B; LEAD-3 (Mono) Study Group. Garber A, et al. Diabetes Obes Metab. 2011 Apr;13(4):348-56. doi: 10.1111/j.1463-1326.2010.01356.x. Diabetes Obes Metab. 2011. PMID: 21205128 Free PMC article. Clinical Trial.
543 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page